<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25843" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neutropenia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Justiz Vaillant</surname>
            <given-names>Angel A.</given-names>
          </name>
          <aff>University of the West Indies</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reynolds</surname>
            <given-names>Samuel B.</given-names>
          </name>
          <aff>USF Health Morsani College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Angel Justiz Vaillant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samuel Reynolds declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25843.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neutropenia is a condition characterized by an abnormally low number of neutrophils, which are granulated leukocytes crucial for the initial immune response to inflammation and infection. Neutrophils ingest, kill, and digest invading microorganisms such as fungi and bacteria. A defect in neutrophil composition, function, or quantity can lead to recurrent infections. Neutropenia can be primary, due to decreased production or ineffective neutrophil activity, or secondary, due to consumption or destruction of neutrophils. Identifying the correct etiology of neutropenia is vital for implementing appropriate management, monitoring, and prognosis. In cases of congenital neutropenia, genetic counseling is necessary to understand the hereditary aspects and implications, making accurate identification of causative factors essential.</p>
        <p>Participants in this course learn to comprehensively review the etiology, presentation, evaluation, and management/prevention of neutropenia. The course emphasizes the importance of distinguishing between primary and secondary causes to tailor treatment effectively. By collaborating with an interprofessional team, including hematologists, genetic counselors, infectious disease specialists, and primary care providers, healthcare professionals can ensure a holistic approach to patient care. This collaboration enhances patient outcomes by integrating diverse expertise, facilitating precise diagnosis, and ultimately improving the quality of life for patients with neutropenia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Select the most relevant diagnostic tests to determine the specific cause of neutropenia in different clinical scenarios.</p></list-item><list-item><p>Differentiate between primary and secondary causes of neutropenia, focusing on bone marrow production versus extramedullary causes.</p></list-item><list-item><p>Implement appropriate treatment strategies based on the underlying etiology of neutropenia, whether it is due to production defects or increased destruction.</p></list-item><list-item><p>Communicate interprofessional team strategies for improving care coordination for better identification, differentiation and treatment of neutropenia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25843&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25843">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25843.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neutrophils are the most common type of leukocytes, known colloquially as white blood cells, that normally circulate as granulocytes along the vascular endothelium in peripheral blood&#x000a0;vessels. Neutrophils play an essential role in immune defenses because they ingest, kill, and digest invading microorganisms, including fungi and bacteria after extravasating through blood vessels, a process better known as transendothelial migration.<xref ref-type="bibr" rid="article-25843.r1">[1]</xref> Failure to carry out this role leads to immunodeficiency, mainly characterized by recurrent infections.<xref ref-type="bibr" rid="article-25843.r2">[2]</xref> Defects in neutrophil function can be quantitative, as seen in neutropenia, or qualitative, as seen in neutrophil dysfunction. The standard circulating neutrophil count should be greater than 1.5 x 10<sup>9</sup>/L. Neutropenia can be classified as mild, moderate, severe, and agranulocytosis.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref>&#x000a0;Please see StatPearls' associated reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17293">Agranulocytosis,</ext-link>" for further information on this topic. Neutropenia classification, per circulating neutrophil count, includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild: 1.0 to 1.5 x 10<sup>9</sup>/L</p>
          </list-item>
          <list-item>
            <p>Moderate: 0.5 to 1.0 x&#x000a0;10<sup>9</sup>/L</p>
          </list-item>
          <list-item>
            <p>Severe: less than 0.5 x&#x000a0;10<sup>9</sup>/L</p>
          </list-item>
          <list-item>
            <p>Agranulocytosis: less than 0.2 x&#x000a0;10<sup>9</sup>/L with absence of neutrophil precursors in bone marrow</p>
          </list-item>
        </list>
        <p>Neutropenia, or a state of low neutrophils, in itself has a wide differential that includes a primary disorder of production in the bone marrow, genetic deficiency, and cyclical deficiency. Additional causes of primary neutropenia include malignant disorders of marrow failure, such as leukopenia, or infiltrative hematologic neoplasms, such as high-grade lymphoma. Neutropenia can also be secondary to marrow extrinsic causes, including autoimmune diseases, cytotoxic chemotherapy, or suppressive illnesses or infections; even antibiotics can be toxic to neutrophils. Multifactorial neutropenia is also not uncommon, and is seen in patients who are on systemic chemotherapy and multiple broad-spectrum antibiotics., for instance.</p>
        <p>Primary neutropenia, with decreased production and marrow hypoplasia, can be due to chronic benign&#x000a0;neutropenia, cyclical neutropenia, or other congenital and genetic neutropenias. Acquired neutropenia can be secondary to cytotoxic drugs, leukemia, drug reactions, or infections. Congenital forms are rare and vary in severity. Some life-threatening neutropenias include leukocyte adhesion deficiency syndromes, Chediak-Higashi syndrome, Shwachman-Diamond syndrome, and chronic granulomatous disease.<xref ref-type="bibr" rid="article-25843.r4">[4]</xref><xref ref-type="bibr" rid="article-25843.r5">[5]</xref></p>
      </sec>
      <sec id="article-25843.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Neutrophils play a primary role in the immune defense against extracellular bacteria, including&#x000a0;<italic toggle="yes">Staphylococci</italic>,&#x000a0;<italic toggle="yes">Streptococci</italic>, and&#x000a0;<italic toggle="yes">Escherichia coli,&#x000a0;</italic>among others. They also protect against fungal infections, including those produced by&#x000a0;<italic toggle="yes">Candida albicans</italic>. Once the neutrophil count is below 1.5 x&#x000a0;10<sup>9</sup>/L, recurrent infections become more common. The monocyte count may increase as a compensatory mechanism.</p>
        <p>Neutropenia can be considered acute (&#x0003c;3 months) or chronic (&#x0003e;3-6 months).<xref ref-type="bibr" rid="article-25843.r6">[6]</xref>&#x000a0;Neutropenia should be evaluated in conjunction with the bone marrow response which also helps clarify the pathophysiology. Circulating neutrophils account for only 3% to 5% of the total, with the remainder sequestered until activated by infection or other stimulus. The clinical significance of this is that even in cases of peripheral neutropenia if bone marrow reserves are adequate, the infectious risk may be mitigated. Neutropenia can be classified by decreased bone marrow reserves (primary) or normal bone marrow reserves (secondary).<xref ref-type="bibr" rid="article-25843.r3">[3]</xref></p>
        <p>
<bold>Decreased Bone Marrow Reserves</bold>
</p>
        <p>Decreased bone marrow reserves cause an initial lack of availability of neutrophils and precursor cells. This can be related to intrinsic or extrinsic factors.</p>
        <list list-type="bullet">
          <list-item>
            <p>Intrinsic factors include genetic mutations (eg, <italic toggle="yes">ELANE, HAX1, WAS&#x000a0;</italic>mutations) or acquired myelodysplastic syndrome, and causes vary by age.</p>
          </list-item>
          <list-item>
            <p>Extrinsic factors limiting neutrophil production can be related to 2 main causes:
<list list-type="bullet"><list-item><p>physical bone marrow infiltration/replacement/restriction&#x02014;eg, leukemia, neuroblastoma, or osteopetrosis</p></list-item><list-item><p>external limiting factors
<list list-type="bullet"><list-item><p>viral or bacterial infections, radiation, drug-induced, alcoholism</p></list-item><list-item><p>nutritional deficiencies of&#x000a0;folate, vitamin B12, and copper&#x000a0;<xref ref-type="bibr" rid="article-25843.r3">[3]</xref></p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Normal Bone Marrow Reserves</bold>
</p>
        <p>Normal bone marrow reserves are common and provide the availability of neutrophils, which are then either destroyed, sequestered, consumed, or ineffectively transported/non-functional.</p>
        <p><bold>Genetic</bold> causes of neutropenia usually affect neutrophil chemotaxis or function. The pathophysiology section will describe the most common genetic syndromes.</p>
        <p>Ineffective neutrophil trafficking and function can be affected at many steps. The primary causes of defective neutrophil function include failure of the following mechanisms:</p>
        <list list-type="bullet">
          <list-item>
            <p>Migration into inflammation sites (abnormal chemotaxis)</p>
          </list-item>
          <list-item>
            <p>Adherence to endothelial cells</p>
          </list-item>
          <list-item>
            <p>Ingestion of bacteria</p>
          </list-item>
          <list-item>
            <p>Production of microbicidal compounds and toxic reactive oxygen species to kill pathogens</p>
          </list-item>
          <list-item>
            <p>Formation of phagolysosomes&#x000a0;<xref ref-type="bibr" rid="article-25843.r5">[5]</xref><xref ref-type="bibr" rid="article-25843.r7">[7]</xref></p>
          </list-item>
        </list>
        <p><bold>Drugs</bold>&#x000a0;can cause both hypoplastic neutropenia from bone marrow suppression or autoimmune neutropenia.<xref ref-type="bibr" rid="article-25843.r8">[8]</xref>&#x000a0;Chemotherapeutic agents are commonly known to cause neutropenia. Levamisole is a veterinary antiparasitic drug that has been frequently used as an adulterant in cocaine and is known to cause agranulocytosis.<xref ref-type="bibr" rid="article-25843.r9">[9]</xref> Other&#x000a0;common drugs known to cause neutropenia include the following:<xref ref-type="bibr" rid="article-25843.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Aminopyrine</p>
          </list-item>
          <list-item>
            <p>Cephalosporins</p>
          </list-item>
          <list-item>
            <p>Dapsone</p>
          </list-item>
          <list-item>
            <p>Heavy metals (eg, arsenic, aluminum phosphate)<xref ref-type="bibr" rid="article-25843.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Hydroxychloroquine</p>
          </list-item>
          <list-item>
            <p>Hydralazine</p>
          </list-item>
          <list-item>
            <p>Lamotrigine</p>
          </list-item>
          <list-item>
            <p>Methimazole</p>
          </list-item>
          <list-item>
            <p>Oxacillin/penicillins</p>
          </list-item>
          <list-item>
            <p>Phenothiazine</p>
          </list-item>
          <list-item>
            <p>Procainamide</p>
          </list-item>
          <list-item>
            <p>Propylthiouracil</p>
          </list-item>
          <list-item>
            <p>Quinidine/quinine</p>
          </list-item>
          <list-item>
            <p>Rituximab</p>
          </list-item>
          <list-item>
            <p>Sulfasalazine</p>
          </list-item>
          <list-item>
            <p>Sulfonamides</p>
          </list-item>
          <list-item>
            <p>Trimethoprim-sulfamethoxazole</p>
          </list-item>
          <list-item>
            <p>Vancomycin</p>
          </list-item>
          <list-item>
            <p>Clozapine (see below)<xref ref-type="bibr" rid="article-25843.r10">[10]</xref><xref ref-type="bibr" rid="article-25843.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>Clozapine is an antipsychotic used for treatment-resistant psychosis and has been underutilized in part due to adverse effects, including severe neutropenia and agranulocytosis (occurring in 3.8% and 0.9% of patients, respectively), requiring stringent hematologic monitoring.<xref ref-type="bibr" rid="article-25843.r13">[13]</xref><xref ref-type="bibr" rid="article-25843.r14">[14]</xref>&#x000a0;The significance of neutropenia is that usage is often avoided despite clozapine being the current most effective treatment for treatment-resistant schizophrenia. A genetic predisposition to developing agranulocytosis is likely involved, and this is an area needing further study.<xref ref-type="bibr" rid="article-25843.r15">[15]</xref><xref ref-type="bibr" rid="article-25843.r16">[16]</xref>&#x000a0;Rechallenge with clozapine is possible in selected cases.<xref ref-type="bibr" rid="article-25843.r14">[14]</xref> Please see StatPearls' associated review on "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/1964">Clozapine</ext-link>" for further details.</p>
        <p><bold>Autoimmune</bold> or anti-neutrophil neutropenia is a common cause of neutropenia. However, autoantibody levels do not closely correlate with the degree of neutropenia. A positive antinuclear antibody (ANA) is suggestive, but not definitive, of autoimmune neutropenia.<xref ref-type="bibr" rid="article-25843.r8">[8]</xref>&#x000a0;Both immunoglobulin (B-cell) and cell-mediated (T-cell, natural killer cell) immunity can be involved. Autoimmune destruction can occur in the bone marrow or peripherally, primarily through monocyte/macrophage elimination via the spleen.<xref ref-type="bibr" rid="article-25843.r6">[6]</xref></p>
        <p>Autoimmune neutropenia in infancy occurs due to antineutrophil antibodies and generally has a benign course; this condition spontaneously resolves about 90% of the time within 2 to 3 years of onset.<xref ref-type="bibr" rid="article-25843.r17">[17]</xref>&#x000a0;Autoimmune neutropenias are more common in adult women, especially those who are between 25 and 40. Symptoms of connective tissue diseases like lupus and Sj&#x000f6;gren syndrome are common. Felty syndrome is a classic example of autoimmune neutropenia characterized by chronic rheumatoid arthritis, splenomegaly, and activated large granular lymphocytes.<xref ref-type="bibr" rid="article-25843.r6">[6]</xref></p>
        <p>Autoimmune destruction of neutrophils has also been observed in these conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Thyroid disease</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease</p>
          </list-item>
          <list-item>
            <p>Chronic autoimmune hepatitis</p>
          </list-item>
          <list-item>
            <p>Granulomatosis with polyangiitis</p>
          </list-item>
          <list-item>
            <p>Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Infections</p>
          </list-item>
          <list-item>
            <p>Hepatitis B and C (although these can acutely cause neutropenia, they are more commonly associated with a chronic immune-mediated form)</p>
          </list-item>
        </list>
        <p><bold>Increased consumption</bold> of neutrophils is common in sepsis and bacterial infections. Neonates are especially prone to neutropenia from sepsis.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref></p>
        <p><bold>Idiopathic neutropenia</bold>, where no cause can be found despite extensive investigation, is common. Results from one study of patients with neutropenia found no identifiable cause in 48% of patients.<xref ref-type="bibr" rid="article-25843.r8">[8]</xref>&#x000a0;Cell-mediated immunity may be an underlying pathology of chronic idiopathic neutropenia through mediation by myeloid-derived suppressor cells, which is an emerging area of study.<xref ref-type="bibr" rid="article-25843.r6">[6]</xref></p>
        <p>Please see <bold>Table.</bold> Causes of Neutropenia for further information.&#x000a0;</p>
      </sec>
      <sec id="article-25843.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Results from a study reported that in the United States, the prevalence of neutropenia was 0.38% among Mexican-Americans, 0.79% among Whites, and 4.5% among Black participants.<xref ref-type="bibr" rid="article-25843.r18">[18]</xref>&#x000a0;Another study&#x000a0;reported that the risk of febrile neutropenia during the chemotherapy regimen course for treating solid tumors was 17%.<xref ref-type="bibr" rid="article-25843.r19">[19]</xref>&#x000a0;Chronic neutropenia is thought to be between 0.12% and 1.4% in the European population.<xref ref-type="bibr" rid="article-25843.r6">[6]</xref>&#x000a0;Men are affected primarily by inherited neutropenias more often than women.<xref ref-type="bibr" rid="article-25843.r20">[20]</xref>&#x000a0;However, autoimmune neutropenia is more common in women than men.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref></p>
      </sec>
      <sec id="article-25843.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Mutations in the gene&#x000a0;<italic toggle="yes">ELANE,</italic>&#x000a0;which encodes neutrophil elastase,&#x000a0;have been found to be the most common cause of congenital and cyclic neutropenia and are autosomal dominant. The gene&#x000a0;<italic toggle="yes">HAX1</italic>&#x000a0;codes for an activator of granulocyte-colony stimulating factor (G-CSF) and is the most common autosomal recessive mutation.<xref ref-type="bibr" rid="article-25843.r21">[21]</xref><xref ref-type="bibr" rid="article-25843.r22">[22]</xref>&#x000a0;Severe congenital neutropenia is used to describe a heterogeneous array of gene mutations leading to variable clinical presentations. Mutations in <italic toggle="yes">ELANE, HAX1,</italic> and many other genes can cause maturation arrest of the neutrophils within the bone marrow, usually at the promyelocyte stage.<xref ref-type="bibr" rid="article-25843.r22">[22]</xref><xref ref-type="bibr" rid="article-25843.r23">[23]</xref>&#x000a0;Severe congenital neutropenia is associated with acute myelogenous leukemia and myelodysplastic syndrome.<xref ref-type="bibr" rid="article-25843.r21">[21]</xref><xref ref-type="bibr" rid="article-25843.r22">[22]</xref></p>
        <p>Cyclic neutropenia is an autosomal dominant congenital neutropenia characterized by oscillating levels of neutrophils, monocytes, lymphocytes, platelets, and reticulocytes, most commonly on a 21-day cycle. Myeloid precursors can be seen in the peripheral blood. This condition is associated with <italic toggle="yes">ELANE</italic> and other mutations. Cyclic neutropenia is generally considered a benign condition but infections can occur during nadirs. G-CSF may be used in these scenarios to hasten neutrophil recovery.<xref ref-type="bibr" rid="article-25843.r22">[22]</xref>&#x000a0;</p>
        <p>Chronic granulomatous disease is one of the classic primary immunodeficiencies of childhood. The clinical presentation of these diseases is recurrent multisystemic infections since childhood. An inherited X-linked recessive disorder, the most commonly observed mutation is in the&#x000a0;<italic toggle="yes">CYBB</italic> gene, manifesting in a deficiency in NADPH oxidase function and failure to produce toxic reactive oxygen species. In brief, neutrophils can ingest microorganisms but cannot kill them, resulting in opportunistic infections with various microbes that include&#x000a0;<italic toggle="yes">Burkholderia</italic><italic toggle="yes">,&#x000a0;</italic><italic toggle="yes">Staphylococcus</italic>,&#x000a0;<italic toggle="yes">Pseudomonas,</italic> and&#x000a0;<italic toggle="yes">Serratia&#x000a0;</italic>species.<xref ref-type="bibr" rid="article-25843.r20">[20]</xref>&#x000a0;A significant consequence is that granulomas can obstruct organs such as the stomach, esophagus, or bladder.&#x000a0;<xref ref-type="bibr" rid="article-25843.r20">[20]</xref></p>
        <p>Leukocyte adhesion deficiency disorders (LAD types 1, 2, and 3) exhibit autosomal recessive inheritance; the functional defect is the inability of neutrophils to adhere to endothelial cells so that they cannot traverse into tissues to ingest and kill bacteria. Three subtypes of LAD syndrome have been identified: In LAD I, a mutation in the beta-integrin 2 gene decreases endothelial adhesion; LAD II results from a transport mutation in the Golgi apparatus; LAD III affects the activation of beta-integrins 1, 2, and 3.<xref ref-type="bibr" rid="article-25843.r24">[24]</xref> &#x000a0;</p>
        <p>Chediak-Higashi syndrome is also an autosomal recessive condition&#x000a0;associated with neutropenia, as well as decreased natural killer and cytotoxic T-cell degranulation. This syndrome is characterized by abnormal chemotaxis preventing neutrophils from reaching bacteria and severely reduced microbicidal activity as lysosomes fail to fuse with phagosomes.<xref ref-type="bibr" rid="article-25843.r25">[25]</xref>&#x000a0;The mutations affect the gene <italic toggle="yes">LYST/CHS1,</italic> which regulates vesicle movement and the lysosomes/organelle size.<xref ref-type="bibr" rid="article-25843.r26">[26]</xref>&#x000a0;Oculocutaneous albinism is a commonly observed clinical feature in patients with Chediak-Higashi syndrome.<xref ref-type="bibr" rid="article-25843.r27">[27]</xref></p>
        <p><italic toggle="yes">WAS</italic>-related disorders: <italic toggle="yes">WAS</italic> is a gene encoding the protein WASp (Wiskott-Aldrich protein) in which mutations cause defective polymerization of the intracellular actin cytoskeleton. Mutations causing abnormal WASp lead to 3 main genetic syndromes:</p>
        <list list-type="order">
          <list-item>
            <p>Wiskott-Aldrich syndrome&#x02014;a genetic disorder characterized by severe immunodeficiency, thrombocytopenia, and eczema&#x02014;is characterized by inactive WASp.&#x000a0;Please see StatPearls' companion reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/31375">Wiskott-Aldrich Syndrome</ext-link>," for further details.</p>
          </list-item>
          <list-item>
            <p>X-linked thrombocytopenia characterized by bleeding, slightly increased risk of infection, and autoimmunity&#x02014;is also characterized by inactive WASp.<xref ref-type="bibr" rid="article-25843.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>On the other hand, gain-of-function <italic toggle="yes">WAS</italic> mutations, as seen in X-linked neutropenia, cause decreased neutrophil quantity but increased neutrophil activity, which shields patients against the infectious complications seen in loss-of-function <italic toggle="yes">WAS</italic> mutations.<xref ref-type="bibr" rid="article-25843.r29">[29]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Shwachman-Diamond syndrome is a rare autosomal recessive disease usually caused by mutations in <italic toggle="yes">SBDS.</italic>&#x000a0;This multisystemic disease has variable presentations, but over 90% of patients with this syndrome have neutropenia.<italic toggle="yes">&#x000a0;</italic>About one-third have chronic neutropenia, while the other two-thirds have neutropenia intermittently. Other cell lines (red cells, platelets) are also impacted. One of the hallmarks of this multisystemic disease is exocrine pancreatic insufficiency caused by the absence of acinar cells, which can spontaneously improve over time. Hepatomegaly&#x000a0;and skeletal deformities are also common. Please see Statpearls' companion review, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/29008">Shwachman-Diamond Syndrome</ext-link>, for more information.<xref ref-type="bibr" rid="article-25843.r30">[30]</xref><xref ref-type="bibr" rid="article-25843.r31">[31]</xref></p>
        <p>Another&#x000a0;unique syndrome falling under immunodeficiency syndromes is the WHIM syndrome, named after its diagnostic tetrad of warts, hypogammaglobulinemia, infections, and myelokathexis (the retention of mature neutrophils in the bone marrow). This syndrome is associated with&#x000a0;<italic toggle="yes">CXCR4</italic>&#x000a0;mutations and results in panleukopenia. Characteristic findings are hypoglobulinemia and mild thrombocytopenia without anemia. Due to the neutrophilic excess in bone marrow, infections can actually lead to increased numbers of mobilized neutrophils in the blood, and patients often respond well to infections.<xref ref-type="bibr" rid="article-25843.r32">[32]</xref>&#x000a0;This phenomenon in WHIM syndrome is likely owed to the unique genetic and autoimmune mechanisms causing neutropenia, as the abnormal neutrophils can also be tagged for apoptosis in the bone marrow.<xref ref-type="bibr" rid="article-25843.r6">[6]</xref></p>
        <p>Another recognized form of hereditary neutropenia is Duffy antigen null neutropenia (formerly termed benign ethnic neutropenia), which is associated with low neutrophil count (&#x0003c;1,500 cells/&#x003bc;L) without an increased infectious risk.&#x000a0;This is a diagnosis of exclusion but is also one of the most common causes of neutropenia in people of African, Arabic, Yeminite Jew, and West Caribbean descent.<xref ref-type="bibr" rid="article-25843.r15">[15]</xref>&#x000a0;One theory proposes that those with&#x000a0;the condition have a greater concentration of neutrophils within the organ compartment instead of the blood; therefore, the total neutrophil count is not low.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref><xref ref-type="bibr" rid="article-25843.r33">[33]</xref></p>
      </sec>
      <sec id="article-25843.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In Chediak-Higashi syndrome, the neutrophils present with giant peroxidase-positive lysosomal granules on peripheral blood smears and in bone marrow precursors.<xref ref-type="bibr" rid="article-25843.r25">[25]</xref><xref ref-type="bibr" rid="article-25843.r34">[34]</xref>&#x000a0;Chronic granulomatous disease is characterized by the presence of granulomas, which are composed of histiocytes that can fuse to form multinucleated giant cells that might be surrounded by other immune cells and covered with fibrotic tissue. The granulomas are often found in hollow viscera (stomach, colon, bladder).<xref ref-type="bibr" rid="article-25843.r20">[20]</xref></p>
      </sec>
      <sec id="article-25843.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>With neutropenia, there is often a history of these conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Recurrent infections</p>
          </list-item>
          <list-item>
            <p>Infections caused by rare bacteria and fungi</p>
          </list-item>
          <list-item>
            <p>Opportunistic infections</p>
          </list-item>
          <list-item>
            <p>Frequent use of antibiotics and antifungals&#x000a0;<xref ref-type="bibr" rid="article-25843.r25">[25]</xref><xref ref-type="bibr" rid="article-25843.r35">[35]</xref><xref ref-type="bibr" rid="article-25843.r36">[36]</xref></p>
          </list-item>
        </list>
        <p>Febrile neutropenia is common, particularly in patients recei ving systemic chemotherapy, and is covered in a different activity. For further information, please see StatPearls' review, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/65103">Febrile Neutropenia</ext-link>."</p>
        <p>Patients with autoimmune neutropenia may demonstrate hepatosplenomegaly or systemic symptoms and signs of thyroid or connective tissue disease. Signs of connective tissue disease include arthralgias, skin rashes, and Raynaud phenomena. Patients with underlying malignancy may complain of various constitutional symptoms that include fatigue, malaise, bone pain, night sweats, or weight loss. Patients with WHIM syndrome will demonstrate warts, and patients with Wiskott-Aldrich syndrome&#x000a0;characteristically&#x000a0;demonstrate eczema.&#x000a0;Chediak-Higashi syndrome is a hyperinflammatory syndrome described above. Physical characteristics include altered skin and eye pigmentation, specifically albinism.<xref ref-type="bibr" rid="article-25843.r37">[37]</xref>&#x000a0;Patients with&#x000a0;Schwachman-Diamond syndrome often present with malabsorption as infants (but with normal sweat chloride as opposed to infants with cystic fibrosis) and malabsorption secondary to pancreatic deficiency. Other physical findings suggestive of either an inherited or acquired neutropenia may include the following:<xref ref-type="bibr" rid="article-25843.r35">[35]</xref><xref ref-type="bibr" rid="article-25843.r38">[38]</xref><xref ref-type="bibr" rid="article-25843.r39">[39]</xref><xref ref-type="bibr" rid="article-25843.r40">[40]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Delayed separation of the umbilical cord (seen with alloimmune neutropenia)&#x000a0;<xref ref-type="bibr" rid="article-25843.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Meningitis</p>
          </list-item>
          <list-item>
            <p>Septicemia</p>
          </list-item>
          <list-item>
            <p>Bacteremia</p>
          </list-item>
          <list-item>
            <p>Skin infections&#x000a0;(eg, pyodermas and abscesses)</p>
          </list-item>
          <list-item>
            <p>Malaise</p>
          </list-item>
          <list-item>
            <p>Gingivitis</p>
          </list-item>
          <list-item>
            <p>Purulent conjunctivitis</p>
          </list-item>
          <list-item>
            <p>Recurrent tonsillitis</p>
          </list-item>
          <list-item>
            <p>Sore throat</p>
          </list-item>
          <list-item>
            <p>Aphthous stomatitis</p>
          </list-item>
          <list-item>
            <p>Otitis media</p>
          </list-item>
          <list-item>
            <p>Coarse facial features</p>
          </list-item>
          <list-item>
            <p>Mucocutaneous candidiasis</p>
          </list-item>
          <list-item>
            <p>Cough</p>
          </list-item>
          <list-item>
            <p>Lung abscesses</p>
          </list-item>
          <list-item>
            <p>Pneumatoceles (air-filled invitations, usually in the lung, after infection, trauma, or with cystic lung disease)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sinus and lung infections</p>
          </list-item>
          <list-item>
            <p>Bronchiectasis</p>
          </list-item>
          <list-item>
            <p>Deep abscesses</p>
          </list-item>
          <list-item>
            <p>Granulomas with catalase-positive organisms</p>
          </list-item>
          <list-item>
            <p>Osteomyelitis</p>
          </list-item>
          <list-item>
            <p>Arthritis</p>
          </list-item>
          <list-item>
            <p>Peritonitis</p>
          </list-item>
          <list-item>
            <p>Intestinal malabsorption</p>
          </list-item>
          <list-item>
            <p>Splenomegaly&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diarrhea &#x000a0; &#x000a0;&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urinary sepsis</p>
          </list-item>
          <list-item>
            <p>Vasculitis</p>
          </list-item>
          <list-item>
            <p>Poor wound healing&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25843.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The immunological investigation of a patient with neutropenia includes the assessment of immunoglobulins, the complement system, phagocytes, and autoantibodies.<xref ref-type="bibr" rid="article-25843.r42">[42]</xref><xref ref-type="bibr" rid="article-25843.r43">[43]</xref></p>
        <p>
<bold>Quantitative Serum Immunoglobulins</bold>
</p>
        <p>IgG, IgM, IgA, and IgE levels can be measured. Elevated IgG and IgM levels may suggest an autoimmune etiology, especially in the presence of other systemic signs.</p>
        <p>
<bold>Blood Lymphocyte Subpopulations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>B lymphocytes (CD19 and CD20) can be measured to assess B-cell levels. Low B-cell levels and hypogammaglobulinemia are seen in some disorders like WHIM syndrome.</p>
          </list-item>
        </list>
        <p><bold>Phagocytic Function</bold> &#x000a0;</p>
        <p>The nitroblue tetrazolium test before and after stimulation with endotoxin shows a positive blue color indicative of NADPH oxidase activity and superoxide generation in response to phagocytized bacteria. This is used for screening, and tests of patients with chronic granulomatous disease will not demonstrate the characteristic positive blue color seen in patients with intact NADPH oxidase activity.<xref ref-type="bibr" rid="article-25843.r44">[44]</xref>&#x000a0;Neutrophil mobility can also be assessed in the medium alone and in the presence of a chemoattractant.</p>
        <p>
<bold>Autoantibodies</bold>
</p>
        <p>Autoantibodies are common in neutropenia and are more commonly detected indirectly. Several limitations to direct antibody testing exist, including low neutrophil count and passive absorption of labeled antibodies to the neutrophil surface, creating false-positive results.<xref ref-type="bibr" rid="article-25843.r6">[6]</xref> A positive ANA is highly suggestive of autoimmune disease, and any manifestations suggesting connective tissue disorders should be investigated with appropriate antibody testing. Patients with thyroid disease are also more likely to have autoimmune neutropenia than the general population. Neonates with neutropenia should be tested for maternal IgG antibodies to fetal neutrophils. Infants and children younger than 3 years in whom autoimmune neutropenia of infancy is suspected should be tested for antineutrophil antibodies (although negative antibodies do not rule this condition out).<xref ref-type="bibr" rid="article-25843.r3">[3]</xref></p>
        <p>
<bold>Complement System Evaluation</bold>
</p>
        <p>Autoimmune neutropenia often involves the activation of the complement system. The complement factors C3 and C4 can be measured by immunoprecipitation tests, ELISA, or Western blotting. CH50 (total complement activity, also called CH100) is a screening assay for the overall activation of the classical complement pathway.<xref ref-type="bibr" rid="article-25843.r45">[45]</xref>&#x000a0;</p>
        <p>
<italic toggle="yes">Complement system functional studies</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Classical pathway assay (using IgM on a microtiter plate)</p>
          </list-item>
          <list-item>
            <p>Alternative pathway assay (using LPS on a microtiter plate)</p>
          </list-item>
          <list-item>
            <p>Mannose pathway assay (using mannose on a microtiter plate)</p>
          </list-item>
        </list>
        <p>
<bold>Microbiological studies</bold>
</p>
        <p>Cultures can be drawn from the blood, urine, stool, sputum, and cerebrospinal fluid.</p>
        <p><bold>Other laboratory investigations</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood cell count&#x000a0; (to determine the absolute neutrophil count)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Blood chemistry</p>
          </list-item>
          <list-item>
            <p>Tumoral markers (although not highly sensitive for each tumor), including CEA, CA 19-9, CA-125, and PSA</p>
          </list-item>
          <list-item>
            <p>Levels of cytokines (granulocyte-colony stimulating factor)</p>
          </list-item>
          <list-item>
            <p>Nutritional deficiencies should be evaluated, including iron, copper, B12, and folate levels</p>
          </list-item>
          <list-item>
            <p>Infectious causes, especially human immunodeficiency virus and hepatitis B/C should be evaluated</p>
          </list-item>
        </list>
        <p>A<bold> peripheral blood smear </bold>is often performed to assess for pseudo neutropenia, which can occur due to in vitro aggregation related to cold agglutins. It may also reveal other hematologic abnormalities.</p>
        <p><bold>Bon</bold><bold>e marrow biopsy&#x000a0;</bold>is performed at the discretion of the hematologist and is especially helpful in distinguishing between low neutrophil reserve and normal reserve bone marrow etiologies. Autoimmune neutropenia will often show a normal bone marrow. Conditions like myelofibrosis, myelodysplastic syndrome, and WHIM syndrome will exhibit characteristic pathology respective to each disease state in addition to variably decreased granulocytic precursors, owing to a shift toward the production of other marrow precursors relevant to the disease.</p>
        <p>
<bold>Genetic Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluorescent in situ hybridization (FISH)</p>
          </list-item>
          <list-item>
            <p>Deoxyribonucleic acid testing (for most congenital disorders)&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Radiologic Imaging Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest x-rays can evaluate for suspected lung infections. However, early chest x-rays may have a lower sensitivity for pneumonia compared to computed tompgraphy (CT) scans.<xref ref-type="bibr" rid="article-25843.r46">[46]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diagnostic&#x000a0;ultrasonography&#x000a0;can evaluate for hepatosplenomegaly.</p>
          </list-item>
          <list-item>
            <p>A CT scan can evaluate suspected abdominal pathologies, including inflammatory bowel syndrome and other suspected malabsorptive states.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25843.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Administration of granulocyte-colony stimulating factor (G-CSF) is the treatment mainstay for neutropenia.<xref ref-type="bibr" rid="article-25843.r47">[47]</xref><xref ref-type="bibr" rid="article-25843.r48">[48]</xref>&#x000a0;G-CSF&#x000a0;is primarily effective in defective myelopoiesis.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref>&#x000a0;The lowest possible G-CSF dose should be given to increase the absolute neutrophil count (ANC) to the desired level, usually greater than&#x000a0;1000 cells/&#x003bc;L.<xref ref-type="bibr" rid="article-25843.r49">[49]</xref>&#x000a0;A recommended starting dose for adults is 5 &#x003bc;g/kg/day, increasing to doses of 10 &#x003bc;g/kg/day if needed for ANC below 1000 cells/uL, but decisions on precise dosing should be tailored to individual patients. The dose for cyclic neutropenia is approximately 1 to 3 &#x000b5;g/kg/d given every 1 to 3 days.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref>&#x000a0;</p>
        <p>Treatment for autoimmune neutropenia with G-CSF is initiated based on the occurrence of infections or stomatitis. Usually, low doses are required as bone marrow reserves should be preserved; a dosage of&#x000a0;0.5 to 3 &#x000b5;g/kg/d of G-CSF can be given every 1 to 3 days to increase the ANC to levels greater than&#x000a0;1000/&#x003bc;L. Immunosuppressive agents are sometimes used in adults for primary autoimmune or chronic idiopathic neutropenia, primarily glucocorticoids, cyclosporine, cyclophosphamide, or methotrexate. However, relapses are common, and the decision for immunosuppressive therapy is patient-specific.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref><xref ref-type="bibr" rid="article-25843.r6">[6]</xref>&#x000a0;Treatment for autoimmune neutropenia secondary to rheumatologic disorders usually involves immunosuppressants for the primary disease. G-CSF has actually been noted to aggravate underlying immune disorders, such as Sweet syndrome.<xref ref-type="bibr" rid="article-25843.r6">[6]</xref></p>
        <p>Prophylactic use of antibiotics and antifungals are routinely utilized in patients with impaired neutrophil function, such as in chronic granulomatous disease.<xref ref-type="bibr" rid="article-25843.r39">[39]</xref><xref ref-type="bibr" rid="article-25843.r50">[50]</xref>&#x000a0;Interferon-gamma has been used in the past, particularly for chronic granulomatous disease, as it theoretically increases the oxidative burst activity of neutrophils, increasing their effectiveness. However, its use is limited by frequent adverse effects such as fevers, myalgia, and malaise.<xref ref-type="bibr" rid="article-25843.r51">[51]</xref><xref ref-type="bibr" rid="article-25843.r52">[52]</xref>&#x000a0;Trimethoprim/sulfamethoxazole is commonly used in chronic granulomatous disease as it covers 5 of the most common infecting pathogens.<xref ref-type="bibr" rid="article-25843.r39">[39]</xref>&#x000a0;The utilization of antimicrobials is compulsory with recurrent infections. Please&#x000a0;see StatPearls' companion review, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/65103">Febrile Neutropenia</ext-link>,"&#x000a0;for further information on this subject.&#x000a0;</p>
        <p>Hematopoietic stem cell transplant (HSCT) is considered in certain neutropenia cases, such as those unresponsive to G-CSF, those with recurrent severe infections, or those who have transformed into a myeloid malignancy. Some clinicians consider&#x000a0;high dosing requirements of G-CSF (&#x0003e;15&#x000a0;&#x000b5;g/kg/d) and certain <italic toggle="yes">ELANE </italic>variants to also be indications.<xref ref-type="bibr" rid="article-25843.r30">[30]</xref>&#x000a0;Neutropenic patients are especially at risk of post-transplant infections, and aggressive post-HSCT prophylaxis is crucial. Graft rejection is also prevalent for all causes of neutropenia.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref>&#x000a0;Transplantation at a high-volume center is recommended.</p>
        <p>A newer class of medication, CXCR4 antagonists, have been studied for the treatment of certain genetic disorders that impair the migration/trafficking of neutrophils to the periphery. Gain-of-function mutations in CXCR4, such as&#x000a0;WHIM syndrome, cause neutrophil retention or myelokathesis in the bone marrow. In April 2024, the CXCR4 antagonist mavorixafor was approved for the treatment of WHIM syndrome.<xref ref-type="bibr" rid="article-25843.r53">[53]</xref>&#x000a0;Another CXCR4 antagonist, plerixafor, has been used for stem cell mobilization in autologous stem cell transplants.<xref ref-type="bibr" rid="article-25843.r54">[54]</xref>&#x000a0;However, plerixafor has not been shown superior to C-GSF in a small trial.<xref ref-type="bibr" rid="article-25843.r55">[55]</xref>&#x000a0;Gene therapy remains investigational for certain causes of neutropenia, but enrollment in clinical trials at high-volume centers is advised for patients with certain neutropenias, including those with chronic granulomatous disease, who are refractory to primary therapies or who are not candidates for HSCT.</p>
      </sec>
      <sec id="article-25843.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Neutropenia can differentiate from antibody deficiency disorders, where a class or different classes of immunoglobulins are below the normal range or absence. These disorders may present clinically by recurrent infections with bacteria and fungi; some are opportunistic pathogens, so the use of antimicrobials to treat infectious diseases is standard.<xref ref-type="bibr" rid="article-25843.r56">[56]</xref> A patient with neutropenia may have an intact acquired immune response but a low number or impaired function of neutrophils. Some complement system deficiencies, eg, C3 deficiency, can manifest with multiple extracellular bacterial infections and neutropenia, but can be ruled out by quantification and functional assessment of the complement system.<xref ref-type="bibr" rid="article-25843.r2">[2]</xref><xref ref-type="bibr" rid="article-25843.r57">[57]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25843.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of neutropenia disorders depends on the cause and organs involved. Neutropenia due to chemotherapy or drugs&#x000a0;generally resolves following growth factor support or cessation of therapy. Cyclic neutropenia, Duffy antigen null neutropenia, and drug-related neutropenia&#x000a0;have good prognoses and are rarely fatal. Serious infections occur in a significant number of patients with neutropenia, and many require repeated admissions. Without treatment, neutropenia is associated with a high risk of death from opportunistic infections.</p>
      </sec>
      <sec id="article-25843.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The primary complications of neutropenia are recurrent and fatal bacterial, viral, and fungal infections.<xref ref-type="bibr" rid="article-25843.r39">[39]</xref>&#x000a0;Another major concern is the development of myelodysplastic syndrome or acute myeloid leukemia, the risk of which is especially high in congenital neutropenias secondary to mutations in&#x000a0;<italic toggle="yes">ELANE</italic>,&#x000a0;<italic toggle="yes">HAX1</italic>,&#x000a0;<italic toggle="yes">WAS,</italic>&#x000a0;<italic toggle="yes">GATA2,&#x000a0;G6PC3,</italic>&#x000a0;and<italic toggle="yes">&#x000a0;<italic toggle="yes">SBDS. </italic></italic>These syndromes are a common cause of mortality in patients with congenital neutropenia. Required monitoring includes complete blood counts with differentials every 3 to 4 months and bone marrow biopsies yearly to monitor for concerning changes.<xref ref-type="bibr" rid="article-25843.r3">[3]</xref><xref ref-type="bibr" rid="article-25843.r30">[30]</xref></p>
        <p>Osteoporosis and osteopenia are common findings in patients with congenital neutropenias, although the exact pathophysiology is unknown. Fortunately, pathological fractures are not common, but patients should still be monitored closely for such.<xref ref-type="bibr" rid="article-25843.r22">[22]</xref>&#x000a0;G-CSF, which is commonly used in severe combined neutropenia, can cause bone pain, which can significantly affect patient compliance.<xref ref-type="bibr" rid="article-25843.r55">[55]</xref>&#x000a0;Second-generation antihistamines, such as loratidine, may be used to alleviate this discomfort.</p>
      </sec>
      <sec id="article-25843.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with any condition causing neutropenia should be extensively educated regarding infection control practices, such as rigorous handwashing and using masks when appropriate. Vaccines should be up to date, and oral hygiene is especially important. All patients with a family history or diagnosis of congenital neutropenia should be offered genetic counseling and prenatal testing where appropriate.&#x000a0;Relatives of these patients can also be tested for disorders and for possible stem cell transplant donation.</p>
      </sec>
      <sec id="article-25843.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Neutropenia is a serious life-threatening disorder with high morbidity and mortality. Thus, the condition is best managed by an interprofessional team that includes primary care providers, hematologists/oncologists, infectious disease specialists, radiologists, oncology nurses, pharmacists, and other health care providers who are crucial to effective care. Nurses caring for these patients must monitor vital signs, and administer medications and blood products. They should know what signs and symptoms to monitor for and when to call the specialist. They can also educate the patient about precautions and warning signs. Pharmacists review the prescription for dose, contraindications, and interactions. They may also help identify any possible drug contributors to neutropenia.</p>
        <p>A strategic approach is equally crucial, involving evidence-based strategies to optimize treatment plans and minimize&#x000a0;adverse effects. Ethical considerations must guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices. Each healthcare professional must be aware of their responsibilities and contribute their unique expertise to the patient's care plan, fostering a multidisciplinary approach. Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance in the management of neutropenia.</p>
      </sec>
      <sec id="article-25843.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25843&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25843">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/neutropenia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25843">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25843/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25843">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25843.s16">
        <fig id="article-25843.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Causes of Neutropenia. Neutropenia can be caused by many different conditions, including infections, cancer, autoimmune diseases, medications, and nutritional deficiencies. Adapted from: Connelly JA, Walkovich K. Diagnosis and therapeutic decision-making for the neutropenic patient. <italic toggle="yes">Hematology Am Soc Hematol Edu Program.</italic> 2021(1):492-503.&#x000a0;Arnold DE, Heimall JR. A review of chronic granulomatous disease. <italic toggle="yes">Adv Ther.</italic> 2017;34(12):2543-2557.&#x000a0;Mart G, Malkan UY, Buyukasik Y. Determination of etiology in patients admitted due to isolated leukopenia. <italic toggle="yes">Medicine (Baltimore).</italic> 2022;101(33):e30116.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Neutropenia" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25843.s17">
        <title>References</title>
        <ref id="article-25843.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filippi</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Neutrophil transendothelial migration: updates and new perspectives.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>May</month>
            <day>16</day>
            <volume>133</volume>
            <issue>20</issue>
            <fpage>2149</fpage>
            <page-range>2149-2158</page-range>
            <pub-id pub-id-type="pmid">30898863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Qurie</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Immunodeficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29763203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connelly</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Walkovich</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and therapeutic decision-making for the neutropenic patient.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2021</year>
            <month>Dec</month>
            <day>10</day>
            <volume>2021</volume>
            <issue>1</issue>
            <fpage>492</fpage>
            <page-range>492-503</page-range>
            <pub-id pub-id-type="pmid">34889413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezaei</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moazzami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aghamohammadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Neutropenia and primary immunodeficiency diseases.</article-title>
            <source>Int Rev Immunol</source>
            <year>2009</year>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>335</fpage>
            <page-range>335-66</page-range>
            <pub-id pub-id-type="pmid">19811314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Severe congenital neutropenia: new genes explain an old disease.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>644</fpage>
            <page-range>644-50</page-range>
            <pub-id pub-id-type="pmid">17917547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fioredda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papadaki</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Palmblad</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Neutropenias: Update on Clinical and Biological Features in Children and Adults.</article-title>
            <source>Hemasphere</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>e814</fpage>
            <pub-id pub-id-type="pmid">36570693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nargund</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Madhumathi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Premalatha</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Appaji</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lakshmidevi</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Accelerated phase of chediak higashi syndrome mimicking lymphoma--a case report.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>e223</fpage>
            <page-range>e223-6</page-range>
            <pub-id pub-id-type="pmid">20661157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Malkan</surname>
                <given-names>UY</given-names>
              </name>
              <name>
                <surname>Buyukasik</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Determination of etiology in patients admitted due to isolated leukopenia.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Aug</month>
            <day>19</day>
            <volume>101</volume>
            <issue>33</issue>
            <fpage>e30116</fpage>
            <pub-id pub-id-type="pmid">35984149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Levamisole: A High Performance Cutting Agent.</article-title>
            <source>Acad Forensic Pathol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>469</fpage>
            <page-range>469-476</page-range>
            <pub-id pub-id-type="pmid">31239995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.</article-title>
            <source>P T</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>12</issue>
            <fpage>765</fpage>
            <page-range>765-768</page-range>
            <pub-id pub-id-type="pmid">27990078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Islam</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Nabi</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Association of clinical complications with nutritional status and the prevalence of leukopenia among arsenic patients in Bangladesh.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>74</fpage>
            <page-range>74-82</page-range>
            <pub-id pub-id-type="pmid">16696181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johannsen</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jimenez-Solem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fink-Jensen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>20451253211072341</fpage>
            <pub-id pub-id-type="pmid">35273789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oloyede</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Whiskey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bachmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dzahini</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Shergill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>MacCabe</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clozapine haematological monitoring for neutropenia: a global perspective.</article-title>
            <source>Epidemiol Psychiatr Sci</source>
            <year>2022</year>
            <month>Nov</month>
            <day>25</day>
            <volume>31</volume>
            <fpage>e83</fpage>
            <pub-id pub-id-type="pmid">36426600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide.</article-title>
            <source>BMC Psychiatry</source>
            <year>2020</year>
            <month>Jun</month>
            <day>05</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>279</fpage>
            <pub-id pub-id-type="pmid">32503471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mijovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>MacCabe</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Clozapine-induced agranulocytosis.</article-title>
            <source>Ann Hematol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>99</volume>
            <issue>11</issue>
            <fpage>2477</fpage>
            <page-range>2477-2482</page-range>
            <pub-id pub-id-type="pmid">32815018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Legge</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.</article-title>
            <source>Pharmacogenomics</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-290</page-range>
            <pub-id pub-id-type="pmid">30767710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flomenblit</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kaplinsky</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Detection of anti-neutrophil antibodies in autoimmune neutropenia of infancy: a multicenter study.</article-title>
            <source>Isr Med Assoc J</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-6</page-range>
            <pub-id pub-id-type="pmid">20550032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Everhart</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Byrd-Holt</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences.</article-title>
            <source>Ann Intern Med</source>
            <year>2007</year>
            <month>Apr</month>
            <day>03</day>
            <volume>146</volume>
            <issue>7</issue>
            <fpage>486</fpage>
            <page-range>486-92</page-range>
            <pub-id pub-id-type="pmid">17404350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weycker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kartashov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Legg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>190</fpage>
            <page-range>190-8</page-range>
            <pub-id pub-id-type="pmid">23824496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rider</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Jameson</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Creech</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2018</year>
            <month>May</month>
            <day>09</day>
            <volume>7</volume>
            <issue>suppl_1</issue>
            <fpage>S2</fpage>
            <page-range>S2-S5</page-range>
            <pub-id pub-id-type="pmid">29746675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dale</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bolyard</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bonilla</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Newburger</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.</article-title>
            <source>Blood Adv</source>
            <year>2022</year>
            <month>Jul</month>
            <day>12</day>
            <volume>6</volume>
            <issue>13</issue>
            <fpage>3861</fpage>
            <page-range>3861-3869</page-range>
            <pub-id pub-id-type="pmid">35476051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skokowa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Touw</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Zeidler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Severe congenital neutropenias.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Jun</month>
            <day>08</day>
            <volume>3</volume>
            <fpage>17032</fpage>
            <pub-id pub-id-type="pmid">28593997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dale</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>How I manage children with neutropenia.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>178</volume>
            <issue>3</issue>
            <fpage>351</fpage>
            <page-range>351-363</page-range>
            <pub-id pub-id-type="pmid">28419427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Etzioni</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Leukocyte adhesion deficiencies.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>1250</volume>
            <fpage>50</fpage>
            <page-range>50-5</page-range>
            <pub-id pub-id-type="pmid">22276660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f6;tt&#x000f6;nen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lanning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saarinen-Pihkala</surname>
                <given-names>UM</given-names>
              </name>
            </person-group>
            <article-title>Chediak-Higashi syndrome: four cases from Northern Finland.</article-title>
            <source>Acta Paediatr</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>92</volume>
            <issue>9</issue>
            <fpage>1047</fpage>
            <page-range>1047-51</page-range>
            <pub-id pub-id-type="pmid">14599068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez-Guiu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ant&#x000f3;n</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Barber&#x000e1;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Navarro-Fern&#x000e1;ndez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fuster</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Couselo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ortu&#x000f1;o</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lozano</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype.</article-title>
            <source>Eur J Haematol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-58</page-range>
            <pub-id pub-id-type="pmid">24112114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nicoli</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Serra-Vinardell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Malicdan</surname>
                <given-names>MCV</given-names>
              </name>
              <name>
                <surname>Introne</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Chediak-Higashi syndrome: a review of the past, present, and future.</article-title>
            <source>Drug Discov Today Dis Models</source>
            <year>2020</year>
            <season>Summer</season>
            <volume>31</volume>
            <fpage>31</fpage>
            <page-range>31-36</page-range>
            <pub-id pub-id-type="pmid">33424983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Worth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thrasher</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>SO</given-names>
              </name>
            </person-group>
            <article-title>How I manage patients with Wiskott Aldrich syndrome.</article-title>
            <source>Br J Haematol</source>
            <year>2019</year>
            <month>May</month>
            <volume>185</volume>
            <issue>4</issue>
            <fpage>647</fpage>
            <page-range>647-655</page-range>
            <pub-id pub-id-type="pmid">30864154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keszei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Record</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kritikou</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wurzer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Geyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thiemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drescher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brauner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>K&#x000f6;cher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baptista</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dahlberg</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>P&#x000fc;tsep</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vandenberghe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Snapper</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Westerberg</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive.</article-title>
            <source>J Clin Invest</source>
            <year>2018</year>
            <month>Aug</month>
            <day>31</day>
            <volume>128</volume>
            <issue>9</issue>
            <fpage>4115</fpage>
            <page-range>4115-4131</page-range>
            <pub-id pub-id-type="pmid">30124469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warren</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Impaired myelopoiesis in congenital neutropenia: insights into clonal and malignant hematopoiesis.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2021</year>
            <month>Dec</month>
            <day>10</day>
            <volume>2021</volume>
            <issue>1</issue>
            <fpage>514</fpage>
            <page-range>514-520</page-range>
            <pub-id pub-id-type="pmid">34889405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burroughs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Woolfrey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shimamura</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-48</page-range>
            <pub-id pub-id-type="pmid">19327581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heusinkveld</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Majumdar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.</article-title>
            <source>J Clin Immunol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>532</fpage>
            <page-range>532-556</page-range>
            <pub-id pub-id-type="pmid">31313072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atallah-Yunes</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ready</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Newburger</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Benign ethnic neutropenia.</article-title>
            <source>Blood Rev</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>37</volume>
            <fpage>100586</fpage>
            <pub-id pub-id-type="pmid">31255364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Srivani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Badhe</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Clinico-hematological profile of Chediak-Higashi syndrome: experience from a tertiary care center in south India.</article-title>
            <source>Indian J Pathol Microbiol</source>
            <year>2011</year>
            <season>Jul-Sep</season>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>547</fpage>
            <page-range>547-51</page-range>
            <pub-id pub-id-type="pmid">21934218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>LYA</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>350</fpage>
            <page-range>350-357</page-range>
            <pub-id pub-id-type="pmid">29751120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dotta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parolini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prandini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabellini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Antolini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kingsmore</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Badolato</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2013</year>
            <month>Oct</month>
            <day>17</day>
            <volume>8</volume>
            <fpage>168</fpage>
            <pub-id pub-id-type="pmid">24134793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabral-Marques</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schimke</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>El Khawanky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Al-Ramadi</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Segundo</surname>
                <given-names>GRS</given-names>
              </name>
              <name>
                <surname>Ochs</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Condino-Neto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Flow Cytometry Contributions for the Diagnosis and Immunopathological Characterization of Primary Immunodeficiency Diseases With Immune Dysregulation.</article-title>
            <source>Front Immunol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>2742</fpage>
            <pub-id pub-id-type="pmid">31849949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestations and outcomes of pediatric chronic neutropenia.</article-title>
            <source>J Formos Med Assoc</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>111</volume>
            <issue>4</issue>
            <fpage>220</fpage>
            <page-range>220-7</page-range>
            <pub-id pub-id-type="pmid">22526211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slack</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>IP</given-names>
              </name>
            </person-group>
            <article-title>Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2018</year>
            <month>May</month>
            <day>09</day>
            <volume>7</volume>
            <issue>suppl_1</issue>
            <fpage>S25</fpage>
            <page-range>S25-S30</page-range>
            <pub-id pub-id-type="pmid">29746681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Herz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nanda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Skin manifestations in primary immunodeficient children.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2011</year>
            <season>Sep-Oct</season>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>494</fpage>
            <page-range>494-501</page-range>
            <pub-id pub-id-type="pmid">21453308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sameshima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwatani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taniguchi-Ikeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yurugi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iijima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morioka</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Periomphalitis with Delayed Umbilical Cord Separation due to Alloimmune Neonatal Neutropenia.</article-title>
            <source>Clin Lab</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>62</volume>
            <issue>11</issue>
            <fpage>2249</fpage>
            <page-range>2249-2252</page-range>
            <pub-id pub-id-type="pmid">28164680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zermatten</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>von Allmen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agyeman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ammann</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Episodes of fever in neutropenia in pediatric patients with cancer in Bern, Switzerland, 1993-2012.</article-title>
            <source>Sci Data</source>
            <year>2019</year>
            <month>Jan</month>
            <day>15</day>
            <volume>6</volume>
            <fpage>180304</fpage>
            <pub-id pub-id-type="pmid">30644854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wuyts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wojciechowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matthieu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aerts</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Juvenile ecthyma gangrenosum caused by Pseudomonas aeruginosa revealing an underlying neutropenia: case report and review of the literature.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>781</fpage>
            <page-range>781-785</page-range>
            <pub-id pub-id-type="pmid">30633375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayatollahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tabei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ramzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kashef</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haghshenas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A fast and easy nitroblue tetrazolium method for carrier screening and prenatal detection of chronic granulomatous disease.</article-title>
            <source>Arch Iran Med</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-8</page-range>
            <pub-id pub-id-type="pmid">17061605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costabile</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Measuring the 50% haemolytic complement (CH50) activity of serum.</article-title>
            <source>J Vis Exp</source>
            <year>2010</year>
            <month>Mar</month>
            <day>29</day>
            <issue>37</issue>
            <pub-id pub-id-type="pmid">20351687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burivong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sricharoen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thachang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soodchuen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maroongroge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leelasithorn</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Early Radiologic Diagnosis of Pulmonary Infection in Febrile Neutropenic Patients: A Comparison of Serial Chest Radiography and Single CT Chest.</article-title>
            <source>Radiol Res Pract</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>8691363</fpage>
            <pub-id pub-id-type="pmid">33680511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pilatova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bencsikova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Demlova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Valik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zdrazilova-Dubska</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment.</article-title>
            <source>Cancer Immunol Immunother</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>12</issue>
            <fpage>1919</fpage>
            <page-range>1919-1929</page-range>
            <pub-id pub-id-type="pmid">29748897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jolis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carabantes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pernas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cantos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Funes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benedit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salar</surname>
                <given-names>A</given-names>
              </name>
              <collab>PRAXIS Study Group</collab>
            </person-group>
            <article-title>Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.</article-title>
            <source>Eur J Cancer Care (Engl)</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>513</fpage>
            <page-range>513-21</page-range>
            <pub-id pub-id-type="pmid">23730920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avalos</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Lazaryan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Copelan</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Can G-CSF cause leukemia in hematopoietic stem cell donors?</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>1739</fpage>
            <page-range>1739-46</page-range>
            <pub-id pub-id-type="pmid">21745453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perparim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nasu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of recombinant human granulocyte-colony stimulating factor alone and in combination with antifungal agents against disseminated trichosporonosis in neutropenic mice.</article-title>
            <source>J Infect Chemother</source>
            <year>1996</year>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>232</fpage>
            <page-range>232-239</page-range>
            <pub-id pub-id-type="pmid">29681373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Marciano</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>DeRavin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zarember</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Malech</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>127</volume>
            <issue>6</issue>
            <fpage>1319</fpage>
            <page-range>1319-26; quiz 1327-8</page-range>
            <pub-id pub-id-type="pmid">21497887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filiz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uygun</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>K&#x000f6;ksoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x0015e;ahin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ye&#x0011f;in</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>In vitro interferon &#x003b3; improves the oxidative burst activity of neutrophils in patients with chronic granulomatous disease with a subtype of gp91phox deficiency.</article-title>
            <source>Cent Eur J Immunol</source>
            <year>2015</year>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">26155184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badolato</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alsina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Azar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bolyard</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dey&#x000e0;-Mart&#x000ed;nez</surname>
                <given-names>&#x000c0;</given-names>
              </name>
              <name>
                <surname>Dickerson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Ezra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hasle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kiani-Alikhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuijpers</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Kulagin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Langguth</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neth</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Olbrich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peake</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodina</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rutten</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Shcherbina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarrant</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Vossen</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Wysocki</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Belschner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bridger</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dubuc</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>MacLeod</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taveras</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Donadieu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.</article-title>
            <source>Blood</source>
            <year>2024</year>
            <month>Jul</month>
            <day>04</day>
            <volume>144</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-45</page-range>
            <pub-id pub-id-type="pmid">38643510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sivachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jfri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ben-Shoshan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vinh</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Popradi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Litvinov</surname>
                <given-names>IV</given-names>
              </name>
            </person-group>
            <article-title>Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?</article-title>
            <source>Skin Therapy Lett</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">35385630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDermott</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Velez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cowen</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>DiGiovanna</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pastrana</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Buck</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rosenzweig</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Merideth</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kuhns</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Malech</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Follmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.</article-title>
            <source>J Clin Invest</source>
            <year>2023</year>
            <month>Oct</month>
            <day>02</day>
            <volume>133</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">37561579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r56">
          <label>56</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ramphul</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Antibody Deficiency Disorder (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">29939682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25843.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Afzali</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Isaeian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sadeghi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moazzami</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parvaneh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Robatjazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ziaee</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Complement deficiency in pediatric-onset systemic lupus erythematosus.</article-title>
            <source>J Lab Physicians</source>
            <year>2018</year>
            <season>Apr-Jun</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-236</page-range>
            <pub-id pub-id-type="pmid">29692593</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
